People with neurogenic orthostatic hypotension are often severely limited in their ability to perform routine daily activities that require walking or standing. There are limited treatment options for people with NOH and we are committed to helping make safe and effective treatments available.
Forty PD patients with mild cognitive deficits will receive droxidopa (a synthetic amino acid that can be converted in the brain to norepinephrine) or a placebo. Each patient will be switched for six-week trials of each regimen. Participants will undergo neuropsychological testing that emphasizes memory, reasoning ability, speed of solving problems and other similar tasks. The neuropsychological testing chosen for this clinical trial corresponds to circuitry of the brain where norepinephrine is actively involved.